VA-REGULA
30.4.2024 09:01:34 CEST | Business Wire | Press release
Regula 70X9 document readers were shipped to three Uber Verification Centers in Warsaw, Krakow, and Poznan, which serve as dedicated hubs where drivers submit their driver’s licenses and identification documents for thorough verification. The shipment was fulfilled by Regula’s Polish distributor, Korporacja Wschód (KW), whose forensic experts also provided special training on how to use the new devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430896042/en/
Regula document readers power the driver verification process for Uber Poland (Photo: Business Wire)
The Regula 70X9 became the core element of Uber’s mission to enhance their safety protocols. It allows Uber employees to perform a comprehensive set of checks to authenticate an ID. The reader automatically identifies the document type; reads the data in all the document zones, including the visual zone, MRZ (machine-readable zone), RFID (radio frequency identification) chips, and barcodes; and cross-compares the obtained text and graphic data. Plus, the supplied document readers are equipped with Automatic Authenticity Control technology. At its core are automated checks that swiftly assess the integrity of the provided documents, detecting any signs of forgery or alteration. All of the above features, together with integrated light sources, significantly reduce the risk of mistakenly verifying forged documents.
The current workflow carried out by Uber’s employees includes:
Step 1. Comparison of the documents provided by the driver with the documents uploaded in the Uber application.
Step 2. Verification of Background Check Certificate.
Step 3. Authenticity verification of passport/ID and driver’s license with the Regula 70X9 reader.
Step 4. Taking a driver’s profile picture.
Step 5. Finalizing verification in the system: data input, document upload, and profile picture upload.
“The process of personally vetting drivers has been, and continues to be, a major logistical challenge, but we believe our efforts will help improve safety in transit. Thanks to the Regula device, the first stage went very smoothly for us. This process, although lengthy, is certainly effective,” says Marcin Konrad Moczyrog, Director and Global Manager at Uber Rides, Central & Eastern Europe.
Prior to the integration of the Regula 70X9, drivers’ documents were verified by Uber’s employees, either manually or via an application based on AI algorithms. The old method had two problems: it was time-consuming, and it did not guarantee protection against high-level forgeries of documents.
“Document fraud is constantly on the rise, and since counterfeited documents are becoming more sophisticated, manual checks are no longer enough. Some inherent document security features may be verified only with special equipment or software solutions. We are honored that our devices have become the cornerstone for a revamped verification process at Uber, and are pleased to see that it’s bearing fruit,” says Maris Kaminskis, Executive Director at Regula Europe.
For additional information, please visit the website.
About Uber
Uber is a technology application connecting passengers and drivers that has revolutionized the way people travel. Since its inception in 2009, Uber has experienced exponential growth, expanding its operations to numerous cities worldwide. Uber operates in more than 10,000 cities across more than 71 countries, making it one of the largest ride-hailing platforms globally.
In Poland, Uber is available in 25 locations.
About Korporacja Wschód
Founded in 1995, Korporacja Wschód is a family-run business that has continually evolved to meet the dynamic needs of high-technology sectors. As the distributor of Regula products in Poland since 1996, we have established ourselves as a vital link in delivering technological solutions to various enforcement and security agencies. Our expertise spans the development, integration, implementation, and distribution of advanced technology equipment, catering primarily to Border Guards, Police, Military, and a range of non-governmental enterprises and institutions. Our collaboration with Regula, a leader in forensic science technologies, underscores our commitment to offering cutting-edge solutions in document verification and security.
Learn more at https://korporacjawschod.pl.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430896042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
